The AVTOZMA ® (tocilizumab-anoh) intravenous (IV) formulation was approved in January 2025 by the FDA to treat the same ...
Incheon, South Korea Monday, October 6, 2025, 16:00 Hrs [IST] Celltrion, Inc. announced that Avtozma (tocilizumab-ano ...
Following regulatory approval earlier this year, South Korean firm Celltrion’ Avtozma (tocilizumab-anoh) intravenous (IV) ...
Biosimilar tocilizumab proves to be a cost-effective treatment for rheumatoid arthritis in Spain, enhancing access to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback